How will immune tolerance protocols affect self-sufficiency goals?
Inhibitor development is a serious complication in haemophilia, and its treatment, immune tolerance therapy, is an expensive part of haemophilia treatment. However, the therapy can lead to an increased lifespan and improved quality of life. If commenced sufficiently early in the disease, it can help to reduce the overall amount of factor VIII concentrate, or other plasma derived therapeutic agents required during life.
Brackmann
H H
HH
Haemophilia Centre, University of Bonn, Germany.
D000328:Adult; D003888:Desensitization, Immunologic / Q000191:economics* / Q000379:methods; D005169:Factor VIII / Q000191:economics / Q000276:immunology* / Q000600:supply & distribution* / Q000627:therapeutic use; D005858:Germany; D006467:Hemophilia A / Q000150:complications / Q000191:economics / Q000276:immunology / Q000628:therapy*; D002836:Hemophilia B / Q000191:economics / Q000276:immunology / Q000628:therapy; D006801:Humans; D007348:Insurance, Health / Q000331:legislation & jurisprudence; D007518:Isoantibodies / Q000096:biosynthesis*; D007592:Joint Diseases / Q000517:prevention & control; D008297:Male; D016896:Treatment Outcome
D007518:Isoantibodies; D005169:Factor VIII